EUVIMEDEUVIMED entdecken
Crossref

Pimavanserin’s Safety Profile: Insights from a Phase 3b Clinical Trial

Ismaeel Yunusa

Journal of Alzheimer’s Disease · 2024

DOI: 10.3233/jad-240274 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Alzheimer’s Disease, 2024. Verfasst von Ismaeel Yunusa. Beteiligte Einrichtung: Department of Clinical Pharmacy and Outcomes Sciences, University of South Carolina, Columbia, SC, USA. Hauptthemen laut MEDLINE: Piperidines, Urea. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The recent Alva et al. Phase 3b study on pimavanserin use in older adults with neurodegenerative diseases (NDDs), specifically including Alzheimer’s disease, vascular dementia, Parkinson’s disease (with or without dementia), frontotemporal dementia, and dementia with Lewy bodies, provides important new data on its safety for managing neuropsychiatric symptoms in this population. This commentary on the study further examines the findings within the broader context of antipsychotic therapy as it has evolved from chlorpromazine to pimavanserin in a continuous search for greater safety. Comparing pimavanserin’s safety and efficacy profile with historical data and regulatory milestones provides a nuanced perspective for clinicians regarding the significance of the drug’s known advantages over prior antipsychotic treatments. More research is needed to determine the full potential of pimavanserin to improve neuropsychiatric symptoms in older adults with NDDs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PiperidinesUreaAgedHumansAntipsychotic AgentsClinical Trials, Phase III as TopicDementiaNeurodegenerative Diseases

Stichwörter der Autor:innen

Alzheimer’ diseasepimavanserinsafety

Substanzen

Antipsychotic AgentspimavanserinPiperidinesUrea

Autor:innen und Institutionen

  • Department of Clinical Pharmacy and Outcomes Sciences, University of South Carolina, Columbia, SC, USA.

Zitieren

APA

Yunusa, I. (2024). Pimavanserin’s Safety Profile: Insights from a Phase 3b Clinical Trial. Journal of Alzheimer’s Disease. https://doi.org/10.3233/jad-240274

Vancouver

Yunusa I. Pimavanserin’s Safety Profile: Insights from a Phase 3b Clinical Trial. Journal of Alzheimer’s Disease. 2024. doi:10.3233/jad-240274

BibTeX
@article{Yunusa2024,
  author = {Yunusa, Ismaeel},
  title = {Pimavanserin’s Safety Profile: Insights from a Phase 3b Clinical Trial},
  journal = {Journal of Alzheimer’s Disease},
  year = {2024},
  doi = {10.3233/jad-240274}
}
Kostenlos starten →